Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Slides:



Advertisements
Similar presentations
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
Advertisements

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide  Asha Johny, Kevin W.
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Olga Sala Torra, Megan Othus, David W
How to Treat MDS without Stem Cell Transplantation
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Sabina Kersting, Leo F. Verdonck 
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia  Vivian.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission  Jennifer L. Holter.
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission  Daniela Damiani,
Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced.
A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation  Philippe Armand, Haesook T. Kim, Daniel.
Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program  Margaret L.
Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia  Daniella.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia  George L. Chen, Hong Liu,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review 
Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia 
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Effects of Conditioning Regimens and T Cell Depletion in Hematopoietic Cell Transplantation for Primary Immune Deficiency  Brandon M. Triplett, Chong.
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic.
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS  Aaron T. Gerds, Ted A. Gooley,
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation  Ibrahim.
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match  Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality  Margaret.
Blood and Marrow Transplant Handbook
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease  Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,
A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic.
Presentation transcript:

Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy  Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Patrick J. Stiff, Roland B. Walter, Martin S. Tallman, Leif Stenke, Harry P. Erba  Biology of Blood and Marrow Transplantation  Volume 21, Issue 3, Pages 559-564 (March 2015) DOI: 10.1016/j.bbmt.2014.10.025 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Flowchart of S0106 patients included in the analysis. Biology of Blood and Marrow Transplantation 2015 21, 559-564DOI: (10.1016/j.bbmt.2014.10.025) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Flowchart of S0106 patients who failed induction after protocol therapy. Biology of Blood and Marrow Transplantation 2015 21, 559-564DOI: (10.1016/j.bbmt.2014.10.025) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Survival of full induction failure cohort. Biology of Blood and Marrow Transplantation 2015 21, 559-564DOI: (10.1016/j.bbmt.2014.10.025) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Survival after failure stratified by transplant. Biology of Blood and Marrow Transplantation 2015 21, 559-564DOI: (10.1016/j.bbmt.2014.10.025) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Survival after transplant stratified by CR at time of transplant (yes versus no), donor (matched related versus not), conditioning regimen intensity (myeloablative versus reduced intensity), and cytogenetic risk (intermediate versus unfavorable). Biology of Blood and Marrow Transplantation 2015 21, 559-564DOI: (10.1016/j.bbmt.2014.10.025) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions